(Q41743218)

8 October 2017

1 reference

title

The cost-benefit of a randomized trial to a health care organization (English)

1 reference

8 October 2017

Hornberger J

1

1 reference

8 October 2017

Eghtesady P

series ordinal

2

1 reference

8 October 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

Contemporary Clinical Trials

8 October 2017

published in

1 reference

8 October 2017

volume

19

1 reference

8 October 2017

issue

2

1 reference

8 October 2017

page(s)

198-211

1 reference

Are clinical trials a cost-effective investment?

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Designing a cost-effective clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Adaptive assignment versus balanced randomization in clinical trials: a decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Clinical and prophylactic trials with assured new treatment for those at greater risk: I. A design proposal.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Clinical and prophylactic trials with assured new treatment for those at greater risk: II. Examples

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Quality-adjusted life years, utility theory, and healthy-years equivalents

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Computerized display of past test results. Effect on outpatient testing

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Measurement of health state utilities for economic appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

A computer program for designing clinical trials with arbitrary survival curves and group sequential testing

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

The case for frequentism in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Septic shock. Hemodynamics and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Shock and tissue injury induced by recombinant human cachectin

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Multiple-organ-failure syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Outcome of patients with abdominal sepsis treated in an intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Time preference for health in cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Methylene blue administration in septic shock: a clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

Meta-analytic stimulus for changes in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900098-6

7 January 2021

10.1016/S0197-2456(97)00098-6

Identifiers

DOI

1 reference

8 October 2017

1 reference